Omnicell (OMCL) Tops Q2 EPS by 14c, Revenues Beat; Offers 3Q EPS Outlook Below Consensus, 3Q Revenue Mid-Point Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. ABBV
7. DFTX
8. USO
9. APGE
10. HOOD

Go back to Omnicell (OMCL) Tops Q2 EPS by 14c, Revenues Beat; Offers 3Q EPS Outlook Below Consensus, 3Q Revenue Mid-Point Guidance Below Consensus

Omnicell Reports Second Quarter 2020 Results

July 28, 2020 4:01 PM EDT

GAAP revenues of $199.6 million and net loss per diluted share of $0.10

Non-GAAP revenues $199.6 million and net income per diluted share of $0.37

Omnicells Response to Coronavirus (COVID-19)

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its second quarter ended June 30, 2020.

GAAP Results

GAAP revenues for the second quarter of 2020 were $199.6 million, down $17.8 million, or 8.2% from the second... More